AI assistant
Sending…
Lifecare ASA — Director's Dealing 2026
Jan 14, 2026
3654_dirs_2026-01-14_0372b19f-3ac6-4da6-b453-3395059605df.pdf
Director's Dealing
Open in viewerOpens in your device viewer
{0}------------------------------------------------
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||
|---|---|---|---|---|
| a) | Name | HANNIBAL INVEST AS | ||
| 2 | Reason for the notification | |||
| a) | Position/status | A company closely associated with Hans Hekland, member of the board ofdirectors of, and primary insider, in Lifecare ASA | ||
| b) | Initial Notification/ Amendment | Initial | ||
| 3 | Details of the issuer | |||
| a) | Name | Lifecare ASA | ||
| b) | LEI | 254900D88MYGZ7JD5P39 | ||
| 4 | Details of the transaction: | |||
| a) | Description of thefinancialinstrument,type ofinstrumentIdentification code | Subscription of sharesin Lifecare ASA, with ISIN NO0013355859Allocation of WarrantsSeries1, with ISIN NO0013709196Allocation of Warrants Series2, with ISIN NO0013709204 | ||
| b) | Nature of thetransaction | Subscription of sharesin the Rights Issue | ||
| c) | Price(s) andvolume(s) | Price | Volume(s)of shares | |
| NOK 0.5 | 200,000 | |||
| Price | Volume(s)of Warrants Series1 | |||
| NOK 0.0 | 150,000 | |||
| Price | Volume(s)of Warrants Series2 | |||
| NOK0.0 | 150,000 | |||
{1}------------------------------------------------
| d) | Aggregatedinformation—Aggregatedvolume—Price | ||
|---|---|---|---|
| Price | Volume(s)of shares | ||
| NOK 100.000 | 200,000 | ||
| Price | Volume(s)Warrants Series 1 | ||
| NOK 0.00 | 150,000 | ||
| Price | Volume(s)Warrants Series 2 | ||
| NOK 0,00 | 150,000 | ||
| e) | Date of thetransaction | 2026-01-14 | |
| f) | Place of thetransaction | Outside a trading venue |
More from Lifecare ASA
Director's Dealing
2026
May 19
Director's Dealing
2026
May 19
Director's Dealing
2026
May 19
Investor Presentation
2026
May 15
Interim / Quarterly Report
2026
May 15
Earnings Release
2026
May 15
Investor Presentation
2026
May 7
Investor Presentation
2026
May 7
Regulatory Filings
2026
May 7
Proxy Solicitation & Information Statement
2026
Apr 1